health benefits of glp 1 drugs GLP-1 & What They Do GLP-1 receptor agonists | How

A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes

Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al

GLP-1 RAs did not improve the change in LVEF (mean difference [MD]): 0.86, p = 0.12, left-ventricular end-diastolic volume (LVEDV) (MD: 3.54, p = 0.11), left-ventricular end-systolic volume (LVESV) (MD: 2.78, p = 0.07) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) (MD: 140.36, p = 0.08)

In a post hoc analysis of the SURPASS-1 trial involving patients with T2DM, the percentage increase in adiponectin levels from baseline ranged from 16% to 23% with tirzepatide compared to a decrease of 0.2% with placebo at week 40 (190)

Liu J, Yin F, Xiao H, Guo L, Gao X

(Kunutsor and colleagues, review, Drugs , 2025